Clinical Trials

94 enrolled

Neuroendocrine Tumors

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

Phase 1 Active not recruiting

Advanced Lung Neuroendocrine Tumor

NCT04750954 2026-03-17

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

130 enrolled

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT04954820 2026-02-05

ReLUTH

146 enrolled

Phase 3 Active not recruiting

Neuroendocrine Tumors, Disease Progression

NCT03972488 2026-01-21

NETTER-2

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT06122610 2026-01-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Phase 1 Recruiting

10 enrolled

EndocrineGastrointestinalNET

Neuroendocrine Tumors

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04234568 2025-12-22

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1 Active not recruiting

31 enrolled 16 charts

Neuroendocrine Tumors

NCT04086485 2025-12-17

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

56 enrolled

EndocrineGastrointestinalNETOther neoplasm

Carcinoid Tumor, Neuroendocrine Tumors

NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Phase 4 Recruiting

6 enrolled

Digestive System Neuroendocrine Tumor G1

NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Phase NA Active not recruiting

195 enrolled

Neuroendocrine Tumors

NCT05178693 2025-11-24

LANTana

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalNET

Neuroendocrine Tumors

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Phase 1 Recruiting

10 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT06398444 2025-09-05

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Phase 2/3 Active not recruiting

74 enrolled

Endocrine

Advanced Neuroendocrine Neoplasm

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

32 enrolled

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

166 enrolled

Neuroendocrine Tumors

NCT06395402 2025-07-22

LUMOD-ID

120 enrolled

Neuroendocrine Tumors

NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Phase 2 Terminated

111 enrolled

Phase EARLY_PHASE1 Active not recruiting

Neoplasms, Neuroendocrine Tumors

NCT04544098 2025-05-02

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

10 enrolled

Phase 1 Active not recruiting

Neuroendocrine Tumors

NCT05249114 2025-03-10

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

6 enrolled

Neuroendocrine Tumors

NCT04261855 2025-02-14

GoTHAM

Phase 1/2 Recruiting

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT02489604 2025-01-13

LUNET

Phase 2 Terminated

70 enrolled

Neuroendocrine Tumors

NCT06607692 2024-10-21

LUPARPED

25 enrolled

Adrenal Gland Neoplasms, Medulloblastoma, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02236910 2024-10-15

Lu-DOTA-TATE

66 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT02754297 2024-08-21

P-PRRT

275 enrolled

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04385992 2023-06-27

NeoLuPaNET

Phase 2 Completed

31 enrolled

Phase 2 Not yet recruiting

Neuroendocrine Tumors

NCT05894486 2023-06-08

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

40 enrolled

Neuroendocrine Tumors

NCT05513469 2023-04-07

Radio-Marker

Phase NA Unknown

20 enrolled

Neuroendocrine Tumors

NCT01237457 2023-03-20

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Phase 2 Completed

143 enrolled

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Phase 3 Completed

37 enrolled

Neuroendocrine Tumors

NCT03590119 2022-11-08

LUTIA

Phase 2/3 Completed

26 enrolled

Neuroendocrine Tumors

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

30 enrolled

231 enrolled 16 charts 2 FDA

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Phase 3 Completed

Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT04039516 2020-08-04

CHARRT

20 enrolled

Endocrine

Carcinoid Heart Disease, Carcinoid Tumor, Serotonin Syndrome

NCT04029428 2020-04-01

POLNETS_PRRT

150 enrolled

Paraganglioma, Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Phase 3 Withdrawn